Emerging Pseudomonas aeruginosa Resistance: Implications in Clinical Practice

Connecticut Medicine

Volumn 68, Issue 1, 2004, Pages 11-15

  Ong, Christine T ^a   Kuti, Joseph L ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; TAZOBACTAM; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIMENTIN; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; GRAM NEGATIVE INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; OUTER MEMBRANE; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PROFESSIONAL PRACTICE; PSEUDOMONAS AERUGINOSA;

EID: 0346970951     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Gales AC, Jones RN, Turnidge J, et al: Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY antimicrobial surveillance program, 1997-1999.
2. Hanberger H, Garcia-Rodriguez JA, Governado M, et al, and the French and Portuguese ICE Study Groups: Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in five European countries. JAMA 1999; 281:1-5.
3. Paladino JA: Economic justification of antimicrobial management programs: Implications of antimicrobial resistance. Am J Health Syst Pharm 2000; 57:10-12.
4. Carmeli Y, Troillet N, Karchmer A, Samore M: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Int Med 1999; 159(10):1127-32.
5. Centers for Disease Control: Semiannual report. Aggregated data from, the National Nosocomial Infections Infections Surveillance (NNIS) System. Rockville, Maryland: United States Department of Health and Human Services, Public Health Service; December 1999.
6. Aeschlimann JR: The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Pharmacotherapy 2003; 7:916-24.
7. Neiderman MS: Appropriate use of antimicrobial agents: Challenges and strategies for improvement. Crit Care Med 2003; 31(2):608-16.
8. Hyatt JM, Schentag JJ: Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2000; 21(Suppl):S9-S11.
9. Hartford Hospital: Antimicrobial Susceptibility Profile. Department of Pathology/Division of Microbiology, January 2003.
10. Neuhauser MM, Weinstein RA, Rydman R, et al: Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289(7):885-8.
11. Troillet JL, Vuagnat A, Combes A, et al: Pseudomonas aeruginosa ventilator-associated pneumonia: Comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34:1047-54.
12. Le Thomas I, Couetdic G, Clermont O, et al: In vivo selection of a target/effiux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001; 48:553-5.
13. Kohler T, Hamzehpour M, Plesiat P, et al: Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41:2540-3.
14. Robillard NJ, Scarpa AL: Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother 1988; 32:535-9.
15. Cho D, Blais J, Tangen K, et al: Prevalence of efflux pump overexpression among clinical isolates of Pseudomonas aeruginosa. Presented at the 39th Interscience Conference on Antimicrobial Agents and chemotherapy, San Francisco, California, September 26-29, 1999.
16. Ziha-Zarifi, I, Lanes C, Kohler T, et al: In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system Mex A-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287-91.
17. Livermore DM: Of pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47:247-50.
18. Jones RN, Kirby JT, Beach ML, et al: Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microb Infect Dis 2002; 43: 239-43.
19. Quinn JP, Dudek EJ, DiVincenzo CA, et al: Emergence of resistance to imipenem during therapy of Pseudomonas aeruginosa infections. J Infect Dis 1986; 154:289-94.
20. Jaccard C, Troillet N, Harbarth S, et al: Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
21. Lepper PM, Grusa E, Reichl H, et al: Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 2920-5.
22. Carmeli Y, Troillet N, Eliopoulos G,et al: Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379.
23. Troillett N, Samore H, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: Risk factors an antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-8.
24. Higgins PG, Fluit AC, Milaovic D, et al: Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. J Antimicro Chemother 2002; 50:293-307.
25. Masuda N, Sakagawa E, Ohya S: Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:645-9.
26. Lesch CA, Itoku GS, Danziger LH, et al: Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001; 41:149-54.
27. Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7.
28. Liser PD, Gardner VM, Sanders CC: Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonized antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999; 43:882-9.
29. Giamarellou H, Antoniadou A: Antipseudomonal Antibiotics. Med Clin N Am 2001; 85(1):19-40.
30. Drusano GL, Louie A, Miller MH: Prevention of emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy [abstract]. Presented at the 98th International Conference of the American Thoracic Society, Atlanta, Georgia, May 2002.
31. Chamot E, Amari EB, Roher P, Delden CV: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47(9):2756-64.
32. Craig WA, Andes D: Aminoglycosides are useful for severe respiratory tract infections. Semin Respir Infect 1997; 12:271-2777.
33. Schmitz FJ, Verhoef J, Fluit AC, and the SENTRY Participants Group: Prevalence of aminoglycoside resistance in 20 European University Hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999; 18:414-21.